Recombinant Vaccines Market Size, Share, Competitive Landscape and Trend Analysis Report by Indication, by End User, by Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

Recombinant Vaccines Market Research, 2031

The global recombinant vaccines market was valued at $8.1 billion in 2021, and is projected to reach $24.7 billion by 2031, growing at a CAGR of 11.4% from 2022 to 2031. Recombinant vaccines are proteins or DNA recombinants that are produced by expression in bacterial or yeast systems. These protein or DNA recombinants are introduced into the host cells where they are identified as a foreign material, and as a result, an immune response is triggered. The advantage of recombinant vaccines is that they can be used for people with weakened immune systems as well. Recombinant proteins have the advantage that they do not get integrated into the host genome so there is no risk of genome infiltration.

The recombinant vaccines market growth is driven by increase in research and development activities for recombinant vaccines, rise in prevalence of infectious diseases and increase in rates of vaccinations globally.

Moreover, increase in incidence of zoonotic diseases, emerging technologies for developing vaccines and rise in number of product approvals also helps in the growth of the recombinant vaccines market size. For instance, in June 2021, Merck and Sanofi received an approval for six-in-one pediatric combination vaccine in the U.S. However, prolong period for introduction of new vaccines is expected to hinder the growth of recombinant vaccines market. Conversely, the high growth potential in untapped emerging economies offers lucrative opportunities for the growth of the market.

Impact of COVID-19 Pandemic on Recombinant Vaccines Market Size

The COVID-19 pandemic affected the recombinant vaccines industry in a positive way, like various other biotechnology industries were affected. The introduction of COVID-19 vaccine was a major step toward reducing the spread of the pandemic and further reducing the associated disease and deaths. The government of every country had made serious effort to ensure seamless delivery of covid-19 recombinant vaccine to the prioritized groups. According to data by Centers for Disease Control and Prevention (CDC), the COVID-19 vaccines available in the U.S. were safe and effective at protecting people from getting seriously ill, being hospitalized, and even dying. Moreover, getting children and teens vaccinated against COVID-19 can help keep them from getting very sick if they do get COVID-19. In addition, the millions of people in the U.S. have received COVID-19 recombinant vaccines under the most intensive safety monitoring program in U.S. history. The World Health Organization (WHO), the challenges and efforts needed to rapidly develop, evaluate and produce this at scale were enormous. It was important to evaluate as many vaccines as possible as market players were unable to predict how many vaccines would turn out to be viable. The World Health Organization was working to ensure that all of them have the chance of being tested at the initial stage of development. For this vaccine’s development, the World Health Organization facilitated the collaboration and accelerated efforts on a scale not seen before and was convening vital communications across the research communities.

Moreover, the advantages of vaccinations among the population also facilitated the production of new and novel vaccines during the pandemic. The recombinant vaccines are proven to be effective in reducing human probability of contracting COVID-19. The vaccinations are known to boost the immune system by teaching the body how to fight threats. Therefore, many countries consider vaccinations as a way to build up the immune system and the manner in which the body reacts to foreign bodies.

Overall, the COVID-19 pandemic had a positive impact on the recombinant vaccines industry owing to the increase in the research and development activities for development of effective vaccines. In addition, the increase in the advantages of vaccines also helped in the growth of the recombinant vaccines market share.

Recombinant Vaccines Market Segmentation

The recombinant vaccines market is segmented into Indication, End User and Distribution Channel. On the basis of indication, the market is classified into human papillomavirus, meningococcal and others. On the basis of end user, the market is bifurcated into pediatric and adult. On the basis of distribution channel, the market is classified into hospitals and vaccination centers. The hospitals segment is further subsegment on the basis of type into private and public. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Market By Indication Segment Review

By indication, the market is classified into human papillomavirus, meningococcal and others. The human papillomavirus segment is anticipated to grow with the largest share throughout the forecast period. This is attributed to increased prevalence of human papillomavirus-related diseases among the population, increase in the healthcare expenditure and increase in the supply of vaccines with the help of authorities such as United Nations International Children's Emergency Fund, World Health Organization and Pan American Health Organization.

Market By End User Segment Review

By end user, the market is classified into pediatric and adult. The adult segment is anticipated to grow with the largest share throughout the forecast period. This is attributed to upsurge in number of adult patients of infectious diseases and increase in production to meet the unmet needs of demand of recombinant vaccines and increase in the efficiency of the recombinant vaccines used in the prevention of various diseases. Moreover, the rise in the prevalence of chronic diseases like cervical and other cancers like cancer of the vulva, vagina, penis and anus also helps in the growth of the market.

Market By Distribution Channel Segment Review

By distribution channel, the market is classified into hospitals and vaccination centers. The hospitals segment is further subsegment on the basis of type into private and public. The hospitals segment is anticipated to grow with the largest recombinant vaccines market share throughout the forecast period. This is attributed to increase in the number of hospitals providing vaccination services and increase the research activities of recombinant vaccines development. Moreover, the increase in the funding by the government organizations for the research and development of recombinant vaccines also contributes in the growth of the market.

Market By Region Review

North America was the dominant region in 2021 and is expected to remain dominant throughout the forecast period, owing to high prevalence rate of chronic disease, increase in the number market players and surge in the vaccination rates in the region. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, owing to the presence of high populace countries such as India and China, which in turn increases the prevalence rate of infectious diseases, geriatric population, and the increasing number of product launch and other trends adopted by the market player.

The key market players operating in this market include, AstraZeneca Plc., Dynavax Technologies Corporation, Emergent BioSolutions Inc., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novavax, Inc., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the recombinant vaccines market analysis from 2021 to 2031 to identify the prevailing recombinant vaccines market opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the recombinant vaccines market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global recombinant vaccines market trends, key players, market segments, application areas, and market growth strategies.

  Recombinant Vaccines Market Report Highlights

Aspects	Details
Market Size By 2031	USD 24.7 billion
Growth Rate	CAGR of 11.4%
Forecast period	2021 - 2031
Report Pages	258
By Indication	Human Papillomavirus Meningococcal Others
By End User	Pediatric Adults
By Distribution Channel	Hospitals Type Private Public Vaccination Centers
By Region	North America  (U.S., Canada, Mexico) Europe  (Germany, France, UK, Italy, Spain, Rest of Europe) Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific) LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players	Pfizer Inc., AstraZeneca Plc., Johnson & Johnson, Serum Institute of India Pvt. Ltd., Novavax, Inc., Merck & Co. Inc., Dynavax Technologies Corporation, GlaxoSmithKline Plc., Sanofi S.A., Emergent BioSolutions Inc.

Analyst Review

The recombinant vaccines are made using bacterial or yeast cells to manufacture the vaccine. A small piece of DNA is taken from the virus or bacterium against which protection is required and is inserted into the manufacturing cells. New product launch and product approval are adopted as a principal strategy to increase the growth of the recombinant vaccines market.

Most of the vaccines in the development are subunit vaccines which do not contain any whole bacteria or viruses at all. Instead, these kinds of vaccines contain polysaccharides (sugars) or proteins from the surface of bacteria or viruses. Moreover, Asia-Pacific is expected to witness the highest CAGR during the analysis period, owing to the presence of high populace countries such as India and China, which in turn increases the prevalence rate of infectious diseases, geriatric population, and the increasing number of product launch and other trends adopted by the market players.

Author Name(s) : Avinash Gadekar | Roshan Deshmukh

Related Tags

• Infectious Diseases
• Immunology And Serology
• Drug Discovery